BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Knie B, Mitra MT, Logishetty K, Chaudhuri KR. Excessive Daytime Sleepiness in Patients with Parkinsonʼs Disease: . CNS Drugs 2011;25:203-12. [DOI: 10.2165/11539720-000000000-00000] [Cited by in Crossref: 68] [Cited by in F6Publishing: 57] [Article Influence: 6.2] [Reference Citation Analysis]
Number Citing Articles
1 Falkenstein M, Karthaus M, Brüne-Cohrs U. Age-Related Diseases and Driving Safety. Geriatrics (Basel) 2020;5:E80. [PMID: 33086572 DOI: 10.3390/geriatrics5040080] [Reference Citation Analysis]
2 Szeto JY, O'Callaghan C, Shine JM, Walton CC, Mowszowski L, Naismith SL, Halliday GM, Lewis SJ. The relationships between mild cognitive impairment and phenotype in Parkinson's disease. NPJ Parkinsons Dis 2015;1:15015. [PMID: 28725684 DOI: 10.1038/npjparkd.2015.15] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
3 Eggert K, Öhlwein C, Kassubek J, Wolz M, Kupsch A, Ceballos-Baumann A, Ehret R, Polzer U, Klostermann F, Schwarz J, Fuchs G, Jost W, Albert A, Haag A, Hermsen A, Lohmüller K, Kuhn K, Wangemann M, Oertel WH; In Cooperation With the German Competence Network on Parkinson’s Disease. Influence of the nonergot dopamine agonist piribedil on vigilance in patients With Parkinson Disease and excessive daytime sleepiness (PiViCog-PD): an 11-week randomized comparison trial against pramipexole and ropinirole. Clin Neuropharmacol 2014;37:116-22. [PMID: 24992083 DOI: 10.1097/WNF.0000000000000041] [Cited by in Crossref: 16] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
4 Ashraf-Ganjouei A, Kheiri G, Masoudi M, Mohajer B, Mojtahed Zadeh M, Saberi P, Shirin Shandiz M, Aarabi MH. White Matter Tract Alterations in Drug-Naïve Parkinson's Disease Patients With Excessive Daytime Sleepiness. Front Neurol 2019;10:378. [PMID: 31057475 DOI: 10.3389/fneur.2019.00378] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
5 Sveinbjornsdottir S. The clinical symptoms of Parkinson's disease. J Neurochem. 2016;139 Suppl 1:318-324. [PMID: 27401947 DOI: 10.1111/jnc.13691] [Cited by in Crossref: 375] [Cited by in F6Publishing: 291] [Article Influence: 62.5] [Reference Citation Analysis]
6 Frank A, Meza-Arriagada F, Salas CO, Espinosa-Bustos C, Stark H. Nature-inspired pyrrolo[2,3-d]pyrimidines targeting the histamine H3 receptor. Bioorg Med Chem 2019;27:3194-200. [PMID: 31176569 DOI: 10.1016/j.bmc.2019.05.042] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
7 Chen JJ. Pharmacologic safety concerns in Parkinson's disease: facts and insights. Int J Neurosci 2011;121 Suppl 2:45-52. [PMID: 22035029 DOI: 10.3109/00207454.2011.620193] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
8 Chondrogiorgi M, Tzarouchi LC, Zikou AK, Astrakas LG, Kosta P, Argyropoulou MI, Konitsiotis S. Multimodal imaging evaluation of excessive daytime sleepiness in Parkinson's disease. Int J Neurosci 2016;126:422-8. [PMID: 26000811 DOI: 10.3109/00207454.2015.1023437] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
9 Capriotti T, Terzakis K. Parkinson Disease. Home Healthc Now. 2016;34:300-307. [PMID: 27243427 DOI: 10.1097/nhh.0000000000000398] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
10 Sobreira-neto MA, Pena-pereira MA, Sobreira EST, Chagas MHN, de Almeida CMO, Fernandes RMF, Tumas V, Eckeli AL. Factors related to excessive sleepiness in patients with Parkinson’s disease. Neurological Research 2019;41:227-33. [DOI: 10.1080/01616412.2018.1548746] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
11 Candel-Parra E, Córcoles-Jiménez MP, Delicado-Useros V, Hernández-Martínez A, Molina-Alarcón M. Evolution of Quality of Life in Persons with Parkinson's Disease: A Prospective Cohort Study. J Clin Med 2021;10:1824. [PMID: 33922142 DOI: 10.3390/jcm10091824] [Reference Citation Analysis]
12 Mkhitarjan T, Areškevičiūtė A, Lund EL, Marner L, Hejl A. Sporadic Fatal Insomnia Presenting with Initial Symptoms of Parkinsonism and Abnormal Dopamine Transporter Imaging. Movement Disord Clin Pract 2022;9:249-51. [DOI: 10.1002/mdc3.13385] [Reference Citation Analysis]
13 Hollingworth SA, McGuire TM, Pache D, Eadie MJ. Dopamine Agonists: Time Pattern of Adverse Effects Reporting in Australia. Drugs Real World Outcomes 2015;2:199-203. [PMID: 27747566 DOI: 10.1007/s40801-015-0028-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
14 Redenšek S, Flisar D, Kojović M, Gregorič Kramberger M, Georgiev D, Pirtošek Z, Trošt M, Dolžan V. Dopaminergic Pathway Genes Influence Adverse Events Related to Dopaminergic Treatment in Parkinson's Disease. Front Pharmacol 2019;10:8. [PMID: 30745869 DOI: 10.3389/fphar.2019.00008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
15 Leopoldo M, Selivanova SV, Müller A, Lacivita E, Schetz JA, Ametamey SM. In vitro and in vivo evaluation of N-{2-[4-(3-Cyanopyridin-2-yl)piperazin-1-yl]ethyl}-3-[(11) C]methoxybenz-amide, a positron emission tomography (PET) radioligand for dopamine D4 receptors, in rodents. Chem Biodivers 2014;11:1298-308. [PMID: 25238073 DOI: 10.1002/cbdv.201400178] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
16 Marinus J, Zhu K, Marras C, Aarsland D, van Hilten JJ. Risk factors for non-motor symptoms in Parkinson's disease. The Lancet Neurology 2018;17:559-68. [DOI: 10.1016/s1474-4422(18)30127-3] [Cited by in Crossref: 79] [Cited by in F6Publishing: 37] [Article Influence: 19.8] [Reference Citation Analysis]
17 Moszczynski A, Murray BJ. Neurobiological Aspects of Sleep Physiology. Neurologic Clinics 2012;30:963-85. [DOI: 10.1016/j.ncl.2012.08.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
18 Lim MM, Szymusiak R. Neurobiology of Arousal and Sleep: Updates and Insights Into Neurological Disorders. Curr Sleep Medicine Rep 2015;1:91-100. [DOI: 10.1007/s40675-015-0013-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 1.4] [Reference Citation Analysis]
19 Taylor NE, Van Dort CJ, Kenny JD, Pei J, Guidera JA, Vlasov KY, Lee JT, Boyden ES, Brown EN, Solt K. Optogenetic activation of dopamine neurons in the ventral tegmental area induces reanimation from general anesthesia. Proc Natl Acad Sci USA. 2016;113:12826-12831. [PMID: 27791160 DOI: 10.1073/pnas.1614340113] [Cited by in Crossref: 113] [Cited by in F6Publishing: 101] [Article Influence: 18.8] [Reference Citation Analysis]
20 Falup-Pecurariu C, Diaconu Ş. Sleep Dysfunction in Parkinson's Disease. Int Rev Neurobiol 2017;133:719-42. [PMID: 28802939 DOI: 10.1016/bs.irn.2017.05.033] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 4.6] [Reference Citation Analysis]
21 van der Heeden JF, Marinus J, Martinez-Martin P, van Hilten JJ. Evaluation of severity of predominantly non-dopaminergic symptoms in Parkinson's disease: The SENS-PD scale. Parkinsonism Relat Disord 2016;25:39-44. [PMID: 26922004 DOI: 10.1016/j.parkreldis.2016.02.016] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
22 Mills RJ, Koufali M, Sharma A, Tennant A, Young CA. Is the Epworth sleepiness scale suitable for use in stroke? Top Stroke Rehabil 2013;20:493-9. [PMID: 24273296 DOI: 10.1310/tsr2006-493] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
23 Solt K, Van Dort CJ, Chemali JJ, Taylor NE, Kenny JD, Brown EN. Electrical stimulation of the ventral tegmental area induces reanimation from general anesthesia. Anesthesiology. 2014;121:311-319. [PMID: 24398816 DOI: 10.1097/aln.0000000000000117] [Cited by in Crossref: 82] [Cited by in F6Publishing: 54] [Article Influence: 10.3] [Reference Citation Analysis]
24 Arnaldi D, Cordano C, De Carli F, Accardo J, Ferrara M, Picco A, Tamburini T, Brugnolo A, Abbruzzese G, Nobili F. Parkinson’s Disease Sleep Scale 2: application in an Italian population. Neurol Sci 2016;37:283-8. [DOI: 10.1007/s10072-015-2409-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
25 Fabbri M, Beracci A, Martoni M, Meneo D, Tonetti L, Natale V. Measuring Subjective Sleep Quality: A Review. Int J Environ Res Public Health 2021;18:1082. [PMID: 33530453 DOI: 10.3390/ijerph18031082] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
26 Dhingra A, Janjua AU, Hack L, Waserstein G, Palanci J, Hermida AP. Exploring Nonmotor Neuropsychiatric Manifestations of Parkinson Disease in a Comprehensive Care Setting. J Geriatr Psychiatry Neurol 2021;34:181-95. [PMID: 32242493 DOI: 10.1177/0891988720915525] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
27 Zhang F, Niu L, Liu X, Liu Y, Li S, Yu H, Le W. Rapid Eye Movement Sleep Behavior Disorder and Neurodegenerative Diseases: An Update. Aging Dis 2020;11:315-26. [PMID: 32257544 DOI: 10.14336/AD.2019.0324] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
28 Goldman JG, Guerra CM. Treatment of Nonmotor Symptoms Associated with Parkinson Disease. Neurologic Clinics 2020;38:269-92. [DOI: 10.1016/j.ncl.2019.12.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
29 Spirgi S, Meyer A, Calabrese P, Gschwandtner U, Fuhr P. Effects of Cognitive Performance and Affective Status on Fatigue in Parkinson's Disease. Dement Geriatr Cogn Dis Extra 2019;9:344-51. [PMID: 31616458 DOI: 10.1159/000498883] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
30 Ly S, Strus E, Naidoo N. Genetic disruption of the putative binding site for Homer on DmGluRA reduces sleep in Drosophila. Sleep 2020;43:zsz190. [PMID: 31418019 DOI: 10.1093/sleep/zsz190] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
31 Videnovic A, Amara AW, Comella C, Schweitzer PK, Emsellem H, Liu K, Sterkel AL, Gottwald MD, Steinerman JR, Jochelson P, Zomorodi K, Hauser RA. Solriamfetol for Excessive Daytime Sleepiness in Parkinson's Disease: Phase 2 Proof-of-Concept Trial. Mov Disord 2021. [PMID: 34191352 DOI: 10.1002/mds.28702] [Reference Citation Analysis]
32 Antonini A, Calandrella D, Merello M, Koutsikos K, Pilleri M. Effects of rotigotine on Parkinson's disease-related sleep disturbances. Expert Opin Pharmacother 2013;14:2571-80. [PMID: 24138154 DOI: 10.1517/14656566.2013.849692] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
33 Wen MC, Ng SY, Heng HS, Chao YX, Chan LL, Tan EK, Tan LC. Neural substrates of excessive daytime sleepiness in early drug naïve Parkinson's disease: A resting state functional MRI study. Parkinsonism Relat Disord 2016;24:63-8. [PMID: 26810915 DOI: 10.1016/j.parkreldis.2016.01.012] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
34 Ly S, Naidoo N. Loss of DmGluRA exacerbates age-related sleep disruption and reduces lifespan. Neurobiol Aging 2019;80:83-90. [PMID: 31103635 DOI: 10.1016/j.neurobiolaging.2019.04.004] [Reference Citation Analysis]
35 Klingelhoefer L, Sokolov E, Chaudhuri KR. Therapeutic options for nocturnal problems in Parkinson's disease and atypical parkinsonian disorders. J Neural Transm (Vienna) 2014;121 Suppl 1:S25-31. [PMID: 24696217 DOI: 10.1007/s00702-014-1202-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
36 Jankovic J, Poewe W. Therapies in Parkinsonʼs disease: . Current Opinion in Neurology 2012;25:433-47. [DOI: 10.1097/wco.0b013e3283542fc2] [Cited by in Crossref: 113] [Cited by in F6Publishing: 41] [Article Influence: 11.3] [Reference Citation Analysis]
37 Shin JY, Hendrix CC. Management of patients with Parkinson disease. Nurse Pract 2013;38:34-43; quiz 44. [PMID: 24048348 DOI: 10.1097/01.NPR.0000434090.96229.5c] [Cited by in Crossref: 15] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
38 Corvol JC, Azulay JP, Bosse B, Dauvilliers Y, Defebvre L, Klostermann F, Kovacs N, Maltête D, Ondo WG, Pahwa R, Rein W, Thobois S, Valis M, Videnovic A, Rascol O; THN102-202 Study Investigators. THN 102 for Excessive Daytime Sleepiness Associated with Parkinson's Disease: A Phase 2a Trial. Mov Disord 2021. [PMID: 34709684 DOI: 10.1002/mds.28840] [Reference Citation Analysis]
39 Bolitho SJ, Naismith SL, Salahuddin P, Terpening Z, Grunstein RR, Lewis SJ. Objective measurement of daytime napping, cognitive dysfunction and subjective sleepiness in Parkinson's disease. PLoS One 2013;8:e81233. [PMID: 24278399 DOI: 10.1371/journal.pone.0081233] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
40 Wilson H, Pagano G, Niccolini F, Muhlert N, Mehta MA, Searle G, Gunn RN, Rabiner EA, Foltynie T, Politis M. The role of phosphodiesterase 4 in excessive daytime sleepiness in Parkinson's disease. Parkinsonism Relat Disord 2020;77:163-9. [PMID: 30824285 DOI: 10.1016/j.parkreldis.2019.02.027] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
41 Donzuso G, Agosta F, Canu E, Filippi M. MRI of Motor and Nonmotor Therapy-Induced Complications in Parkinson's Disease. Mov Disord 2020;35:724-40. [PMID: 32181946 DOI: 10.1002/mds.28025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
42 Yoo SW, Kim JS, Oh YS, Ryu DW, Lee KS. Excessive daytime sleepiness and its impact on quality of life in de novo Parkinson's disease. Neurol Sci 2019;40:1151-6. [PMID: 30820762 DOI: 10.1007/s10072-019-03785-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
43 Lin C, Chang T, Chang M. Dysosmia Is a Predictor of Motor Function and Quality of Life in Patients with Parkinson’s Disease. JPM 2022;12:754. [DOI: 10.3390/jpm12050754] [Reference Citation Analysis]
44 Moreau C, Delval A, Defebvre L, Dujardin K, Duhamel A, Petyt G, Vuillaume I, Corvol JC, Brefel-Courbon C, Ory-Magne F, Guehl D, Eusebio A, Fraix V, Saulnier PJ, Lagha-Boukbiza O, Durif F, Faighel M, Giordana C, Drapier S, Maltête D, Tranchant C, Houeto JL, Debû B, Sablonniere B, Azulay JP, Tison F, Rascol O, Vidailhet M, Destée A, Bloem BR, Bordet R, Devos D; Parkgait-II study group. Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial. Lancet Neurol 2012;11:589-96. [PMID: 22658702 DOI: 10.1016/S1474-4422(12)70106-0] [Cited by in Crossref: 117] [Cited by in F6Publishing: 34] [Article Influence: 11.7] [Reference Citation Analysis]
45 Swick TJ. Parkinson's disease and sleep/wake disturbances. Parkinsons Dis 2012;2012:205471. [PMID: 23326757 DOI: 10.1155/2012/205471] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
46 Lenka A, Padmakumar C, Pal PK. Treatment of Older Parkinson's Disease. Int Rev Neurobiol 2017;132:381-405. [PMID: 28554416 DOI: 10.1016/bs.irn.2017.01.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
47 Lurie DJ, Kessler D, Bassett DS, Betzel RF, Breakspear M, Kheilholz S, Kucyi A, Liégeois R, Lindquist MA, McIntosh AR, Poldrack RA, Shine JM, Thompson WH, Bielczyk NZ, Douw L, Kraft D, Miller RL, Muthuraman M, Pasquini L, Razi A, Vidaurre D, Xie H, Calhoun VD. Questions and controversies in the study of time-varying functional connectivity in resting fMRI. Netw Neurosci 2020;4:30-69. [PMID: 32043043 DOI: 10.1162/netn_a_00116] [Cited by in Crossref: 125] [Cited by in F6Publishing: 86] [Article Influence: 62.5] [Reference Citation Analysis]
48 Beratis IN, Andronas N, Fragkiadaki S, Kontaxopoulou D, Pavlou D, Papantoniou P, Stamelou M, Stefanis L, Yannis G, Papageorgiou SG. Exploring the association of the Comprehensive Trail Making Test with driving indexes in patients with Parkinson’s disease. Transportation Research Part F: Traffic Psychology and Behaviour 2018;59:535-44. [DOI: 10.1016/j.trf.2017.10.007] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
49 Loomis S, McCarthy A, Baxter C, Kellett DO, Edgar DM, Tricklebank M, Gilmour G. Distinct pro-vigilant profile induced in rats by the mGluR5 potentiator LSN2814617. Psychopharmacology (Berl) 2015;232:3977-89. [PMID: 25902875 DOI: 10.1007/s00213-015-3936-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
50 Leng Y, Goldman SM, Cawthon PM, Stone KL, Ancoli-Israel S, Yaffe K. Excessive daytime sleepiness, objective napping and 11-year risk of Parkinson's disease in older men. Int J Epidemiol 2018;47:1679-86. [PMID: 29873737 DOI: 10.1093/ije/dyy098] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 5.7] [Reference Citation Analysis]
51 Dong H, Chen ZK, Guo H, Yuan XS, Liu CW, Qu WM, Huang ZL. Striatal neurons expressing dopamine D1 receptor promote wakefulness in mice. Curr Biol 2022:S0960-9822(21)01702-4. [PMID: 35021048 DOI: 10.1016/j.cub.2021.12.026] [Reference Citation Analysis]
52 Mantovani S, Smith SS, Gordon R, O'Sullivan JD. An overview of sleep and circadian dysfunction in Parkinson's disease. J Sleep Res 2018;27:e12673. [PMID: 29493044 DOI: 10.1111/jsr.12673] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
53 Xiang W, Sun YQ, Teoh HC. Comparison of nocturnal symptoms in advanced Parkinson's disease patients with sleep disturbances: pramipexole sustained release versus immediate release formulations. Drug Des Devel Ther 2018;12:2017-24. [PMID: 30013321 DOI: 10.2147/DDDT.S160300] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
54 Hyacinthe C, Barraud Q, Tison F, Bezard E, Ghorayeb I. D1 receptor agonist improves sleep-wake parameters in experimental parkinsonism. Neurobiol Dis 2014;63:20-4. [PMID: 24211719 DOI: 10.1016/j.nbd.2013.10.029] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
55 Gong L, Li H, Yang D, Peng Y, Liu D, Zhong M, Zhang B, Xu R, Kang J. Striatum Shape Hypertrophy in Early Stage Parkinson's Disease With Excessive Daytime Sleepiness. Front Neurosci 2019;13:1353. [PMID: 31992965 DOI: 10.3389/fnins.2019.01353] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
56 Mao Q, Qin WZ, Zhang A, Ye N. Recent advances in dopaminergic strategies for the treatment of Parkinson's disease. Acta Pharmacol Sin 2020;41:471-82. [PMID: 32112042 DOI: 10.1038/s41401-020-0365-y] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 12.5] [Reference Citation Analysis]
57 Tramontano M, De Angelis S, Galeoto G, Cucinotta MC, Lisi D, Botta RM, D'ippolito M, Morone G, Buzzi MG. Physical Therapy Exercises for Sleep Disorders in a Rehabilitation Setting for Neurological Patients: A Systematic Review and Meta-Analysis. Brain Sci 2021;11:1176. [PMID: 34573197 DOI: 10.3390/brainsci11091176] [Reference Citation Analysis]
58 Redenšek S, Flisar D, Kojović M, Kramberger MG, Georgiev D, Pirtošek Z, Trošt M, Dolžan V. Genetic variability of inflammation and oxidative stress genes does not play a major role in the occurrence of adverse events of dopaminergic treatment in Parkinson's disease. J Neuroinflammation 2019;16:50. [PMID: 30813952 DOI: 10.1186/s12974-019-1439-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
59 Gossard TR, Trotti LM, Videnovic A, St Louis EK. Restless Legs Syndrome: Contemporary Diagnosis and Treatment. Neurotherapeutics 2021;18:140-55. [PMID: 33880737 DOI: 10.1007/s13311-021-01019-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Generali JA, Cada DJ. Modafinil: Parkinson disease-related somnolence. Hosp Pharm 2014;49:612-4. [PMID: 25477578 DOI: 10.1310/hpj4907-612] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
61 Zesiewicz TA, Martinez-martin P. Effects of rotigotine transdermal system on non-motor symptoms in Parkinson’s disease: an overview. Expert Review of Neurotherapeutics 2014;13:1329-42. [DOI: 10.1586/14737175.2013.859986] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
62 Bryant M, Rintala D, Hou J, Rivas S, Fernandez A, Lai E, Protas E. The Relation of Falls to Fatigue, Depression and Daytime Sleepiness in Parkinson’s Disease. Eur Neurol 2012;67:326-30. [DOI: 10.1159/000335877] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]